Pharmacodynamic effects in the cardiovascular system: The modeller's view

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 3, 2010, Pages 243-249

  Fink, Martin ^a,b   Noble, Denis ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; INWARDLY RECTIFYING POTASSIUM CHANNEL; ION CHANNEL; IVABRADINE; POTASSIUM CHANNEL HERG; RANOLAZINE; SOTALOL;

AFTERHYPERPOLARIZATION; CALCIUM CURRENT; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; DISEASE SIMULATION; EXPERIMENTAL MODEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; LONG QT SYNDROME; MATHEMATICAL MODEL; PRIORITY JOURNAL; SODIUM CURRENT; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; ION CHANNELS; MARKOV CHAINS; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS;

EID: 77149178709     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00534.x     Document Type: Conference Paper

References (34)

1. Thomsen MB, Oros A, Schoenmakers M, van Opstal JM, Maas JN, Beekman JDM et al. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 2007 73 : 521 530.
2. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005 2 : 507 517.
3. Roepke TK, Abbott GW. Pharmacogenetics and cardiac ion channels. Vascul Pharmacol 2006 44 : 90 106.
4. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990 81 : 686 690.
5. + current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993 7 (Suppl. 3 599 604.
6. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001 103 : 2004 2013.
7. Valentin J-P, Hoffmann P, Clerck FD, Hammond TG, Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 2004 49 : 171 181.
8. Gaborit N, Bouter SL, Szuts V, Varro A, Escande D, Nattel S et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 2007 582 : 675 693.
9. Szentadrassy N, Banyasz T, Biro T, Szabo G, Toth BI, Magyar J et al. Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium. Cardiovasc Res 2005 65 : 851 860. (Pubitemid 40249729)
10. Sekiya S, Ichikawa S, Tsutsumi T, Harumi K. Nonuniform action potential durations at different sites in canine left ventricle. Jpn Heart J 1983 24 : 935 945.
11. Noble D. Computational models of the heart and their use in assessing the actions of drugs. J Pharmacol Sci 2008 107 : 107 117.
12. DiFrancesco D. The contribution of the 'pacemaker' current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991 434 : 23 40.
13. 2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3. Heart Rhythm 2008 5 : 1444 1452.
14. Brennan T, Fink M, Rodriguez B, Tarassenko LT. Modelling effects of sotalol on action potential morphology using a novel Markov model of the HERG channel. In : Jarm T, Kramar P, Zupanic A (eds). MEDICON 2007. Springer, Berlin Heidelberg, 2007 50 3.
15. Starmer CF, Undrovinas AI, Scamps F, Vassort G, Nesterenko VV, Rosenshtraukh LV. Ethacizin blockade of calcium channels: a test of the guarded receptor hypothesis. Am J Physiol 1989 257 : H1693 704.
16. Zilberter YI, Starmer CF, Grant AO. Open Na+ channel blockade: multiple rest states revealed by channel interactions with disopyramide and quinidine. Am J Physiol 1994 266 : H2007 17.
17. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 2007 292 : H66 75.
18. Shannon TR, Wang F, Puglisi J, Weber C, Bers DM. A mathematical treatment of integrated Ca dynamics within the ventricular myocyte. Biophys J 2004 87 : 3351 3371.
19. + current to repolarization of the human ventricular action potential. Prog Biophys Mol Biol 2008 96 : 357 376.
20. 2+ and electrical alternans in cardiac myocytes: role of CAMKII and repolarizing currents. Am J Physiol Heart Circ Physiol 2007 292 : H2854 66.
21. Burgess MJ. Relation of ventricular repolarization to electrocardiographic T wave-form and arrhythmia vulnerability. Am J Physiol Heart Circ Physiol 1979 236 : 391 402.
22. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Diego JMD, Fish JM et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004 110 : 904 910. (Pubitemid 39136212)
23. Bril A, Forest MC, Cheval B, Faivre JF. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. Cardiovasc Res 1998 37 : 130 140.
24. Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 2008 51 : 581 589.
25. Bányász T, Horváth B, Virág L, Bárándi L, Szentandrássy N, Harmati G et al. Reverse rate dependency is an intrinsic property of canine cardiac preparations. Cardiovasc Res 2009 84 : 273 244.
26. Antzelevitch C. Modulation of transmural repolarization. Ann NY Acad Sci 2005 1047 : 314 323.
27. Taggart P, Sutton PM, Opthof T, Coronel R, Trimlett R, Pugsley W et al. Transmural repolarisation in the left ventricle in humans during normoxia and ischaemia. Cardiovasc Res 2001 50 : 454 462.
28. 2+ current. Circ Res 1989 64 : 977 990.
29. Tweedie D, Harding SE, MacLeod KT. Sarcoplasmic reticulum Ca content, sarcolemmal Ca influx and the genesis of arrhythmias in isolated guinea-pig cardiomyocytes. J Mol Cell Cardiol 2000 32 : 261 272.
30. 2+ exchange current in Cs(+)-induced early afterdepolarizations in Purkinje fibers. J Cardiovasc Electrophysiol 1994 5 : 933 944.
31. Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol 2006 29 : 290 295.
32. Guo D, Zhou J, Zhao X, Gupta P, Kowey PR, Martin J et al. L-type calcium current recovery versus ventricular repolarization: preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm 2008 5 : 271 279.
33. Bottino D, Penland RC, Stamps A, Traebert M, Dumotier B, Georgiva A et al. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol 2006 90 : 414 443.
34. Bril A, Faivre JF, Forest MC, Cheval B, Gout B, Linée P et al. Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations. J Pharmacol Exp Ther 1995 273 : 1264 1272.